{"nctId":"NCT03732833","briefTitle":"MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines","startDateStruct":{"date":"2018-11-05","type":"ACTUAL"},"conditions":["Lateral Canthal Lines","Glabellar Lines"],"count":425,"armGroups":[{"label":"MT10109L Dose 1 + Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: MT10109L","Drug: Placebo"]},{"label":"MT10109L Dose 1 + MT10109L Dose 2","type":"EXPERIMENTAL","interventionNames":["Drug: MT10109L"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"MT10109L","otherNames":["NivobotulinumtoxinA"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n-Female participants must not be pregnant or planning to get pregnant and willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period.\n\nExclusion Criteria:\n\n* Known immunization or hypersensitivity to any botulinum toxin serotype.\n* Any medical condition that may put the participant at increased risk with exposure to MT10109L including diagnosed myasthenia gravis, Eaton Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function.\n* History of facial nerve palsy.\n* Any uncontrolled systemic disease.\n* Anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than study intervention).\n* Anticipated need for surgery or overnight hospitalization during the study.\n* Prior exposure to botulinum toxin of any serotype for any reason.\n* Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow lift, or related procedures (eg, eyelid \\[blepharoplasty\\] and/or eyebrow surgery).\n* Prior facial treatment with permanent soft tissue fillers, synthetic implantation (eg, Gore-Tex®), and/or autologous fat transplantation.\n* Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.\n* Females who are pregnant, nursing, or planning a pregnancy during the study.\n* Participants who plan for an extended absence away from the immediate area of the study site that would preclude them from returning for all protocol-specified study visits.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND PARTICIPANT Assessments of LCL Severity at Maximum Smile at Day 30","description":"The outcome measured is the percentage of participants who had a ≥2-grade improvement from baseline LCL severity at maximum smile according to investigator and participant FWS ratings at Day 30.\n\nBoth the INVESTIGATOR AND PARTICIPANT evaluate the LCL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe. The primary endpoint is achieved and recorded as a count only when BOTH INVESTIGATOR AND PARTICIPANT assess the improvement in FWS from baseline to be ≥ 2-grade improvement. Therefore, the primary endpoint is the proportion/percentage of participants who meet the dual assessment threshold of ≥2-grade improvement from baseline.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Responders for INVESTIGATOR Assessments of Lateral Canthal Lines (LCL) Severity at Maximum Smile Using the Facial Wrinkle Scale With Photonumeric Guide (FWS)","description":"The outcome here only considers the INVESTIGATOR assessments (excludes the participant assessment). The investigator evaluates the participant's LCL severity using a 4-point scale (0 to 3) where 0=none and 3=severe. A Responder was defined as one achieving a ≥2-grade improvement from baseline at maximum smile at Day 30.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"64","spread":null}]}]}]},{"type":"SECONDARY","title":"The Duration of Lateral Canthal Lines (LCL) Treatment in Participants Who Achieved a Rating of ≥ 2-grade Improvement From Baseline in LCL Severity at Maximum Smile at Day 30 According to Investigator Assessments Using the FWS","description":"The investigator evaluates the participant's LCL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Reporting Mostly Satisfied/Very Satisfied on the Facial Line Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 for Lateral Canthal Lines (LCL)","description":"The Satisfaction Question 5 grades facial line treatment satisfaction on a 5-point scale (-2 to 2) where -2=Very dissatisfied and 2=Very satisfied.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"122","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Responders for Investigator Assessments of Lateral Canthal Lines (LCL) Severity at Rest Using the Facial Wrinkle Scale (FWS)","description":"The investigator evaluates the participant's LCL severity using a 4-point scale (0 to 3) where 0=none and 3=severe.\n\nAmong Participants Who Were Rated At least Mild at Rest at Baseline, where a Responder was Defined as Achieving a ≥1-grade Improvement from Baseline at Day 30. The outcome measured here is the proportion of participants who achieved a ≥1-grade improvement from baseline LCL severity at rest based on investigator FWS rating.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"107","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Experienced a Treatment Emergent Adverse Event (TEAEs)","description":"This section focuses primarily on TEAEs, i.e., AEs that started or worsened after the first dose of study intervention and within 30 days after the last dose. The safety analyses were conducted in the Safety population. Unless otherwise noted, safety results refer to TEAEs.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"106","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Systolic Blood Pressure (BP)","description":"The outcome reported here is the mean change in Systolic BP from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"11.60"},{"groupId":"OG001","value":"-0.4","spread":"12.29"},{"groupId":"OG002","value":"-0.3","spread":"13.67"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Diastolic Blood Pressure (BP)","description":"The outcome reported here is the mean change in Diastolic BP from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"8.61"},{"groupId":"OG001","value":"-1.4","spread":"8.34"},{"groupId":"OG002","value":"-0.7","spread":"9.28"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Pulse Rate","description":"The outcome reported here is the mean change in Pulse Rate from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"11.2"},{"groupId":"OG001","value":"0.9","spread":"10.54"},{"groupId":"OG002","value":"-0.4","spread":"11.34"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Respiratory Rate","description":"The outcome reported here is the mean change in Respiratory Rate from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.03"},{"groupId":"OG001","value":"-0.3","spread":"2.04"},{"groupId":"OG002","value":"-0.6","spread":"2.47"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Electrocardiogram (ECG) Parameters - Mean Heart Rate","description":"The outcome reported here is a mean change in mean heart rate from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"10.34"},{"groupId":"OG001","value":"4.2","spread":"9.35"},{"groupId":"OG002","value":"2.7","spread":"8.34"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Electrocardiogram (ECG) Parameters - PR Interval","description":"The outcome reported here is a mean change in PR interval from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"9.36"},{"groupId":"OG001","value":"-0.7","spread":"12.37"},{"groupId":"OG002","value":"0.0","spread":"11.09"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QRS Duration","description":"The outcome reported here is a mean change in QRS duration from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"6.16"},{"groupId":"OG001","value":"0.4","spread":"5.35"},{"groupId":"OG002","value":"1.6","spread":"8.06"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QT Interval","description":"The outcome reported here is a mean change in QT interval from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.6","spread":"25.07"},{"groupId":"OG001","value":"-10.4","spread":"21.96"},{"groupId":"OG002","value":"-9.2","spread":"21.26"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QTcB Interval","description":"The outcome reported here is a mean change in QTcB interval from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"17.34"},{"groupId":"OG001","value":"1.6","spread":"16.64"},{"groupId":"OG002","value":"-1.5","spread":"16.3"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QTcF Interval","description":"The outcome reported here is a mean change in QTcF interval from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"14.21"},{"groupId":"OG001","value":"-2.7","spread":"13.57"},{"groupId":"OG002","value":"-4.2","spread":"13.65"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Electrocardiogram (ECG) Parameters - RR Interval","description":"The outcome reported here is a mean change in RR interval from baseline to study exit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.6","spread":"137.27"},{"groupId":"OG001","value":"-53.0","spread":"120.85"},{"groupId":"OG002","value":"-35.0","spread":"114.66"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Binding and Neutralizing Antibodies","description":"Only samples that tested positive in the binding antibody confirmatory assay were evaluated for neutralizing antibodies. The participants with positive neutralizing antibodies are only shown.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":86},"commonTop":["Injection site pain","Nasopharyngitis","Headache","Injection site haemorrhage","Upper respiratory tract infection"]}}}